Electrospun Polycaprolactone (PCL)/Microbial Chondroitin Sulfate (CS)-Based Transdermal Patches for Optimized Ribociclib Delivery

Breast cancer remains the most prevalent cancer worldwide and a leading cause of mortality in women, demanding advanced drug delivery strategies. Ribociclib, a CDK4/6 inhibitor used in hormone-dependent breast cancer therapy, is effective but requires high oral doses, leading to severe systemic toxicity. To overcome this limitation, we developed electrospun PCL/CS-based transdermal patches designed to enhance drug bioavailability, prolong half-life, and minimize side effects. Extensive characterization confirmed the structural integrity and performance of the patches, demonstrating high swelling capacity (81–93%), superior thickness uniformity (95–100%), and exceptional folding endurance (1000–1540 cycles). The patches exhibited excellent weight homogeneity (92–99%) for consistent drug distribution, while adhesion strength (144–386 kPa) ensured stable skin attachment. HPLC analysis revealed sustained Ribociclib release (∼95% over 48 h), and ex vivo rat skin diffusion studies confirmed high permeability (68–81%), indicating effective transdermal absorption. Drug retention efficiency exceeded 95% in both the reservoir and drug release layers. Biocompatibility assessments with L-929 fibroblasts demonstrated excellent cell viability (90–95%), while MCF-7 breast cancer cells exhibited potent cytotoxicity (93–94%), comparable to standard Ribociclib treatment. Despite the therapeutic potential of transdermal drug delivery systems (TDDS), Ribociclib has been scarcely explored in this context. This study pioneers a promising alternative for controlled, sustained drug release, potentially revolutionizing breast cancer treatment by improving patient compliance, reducing systemic toxicity, and enhancing therapeutic outcomes.